Zobrazeno 1 - 10
of 26
pro vyhledávání: '"ALK Gene Amplification"'
Autor:
Kazuhisa Takahashi, Shoko Ueda, Hironori Ninomiya, Mario Suzuki, Takehito Shukuya, Yuta Arai, Tomohito Takeshige, Takuo Hayashi, Akihide Kondo
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 715-719 (2021)
Thoracic Cancer
Thoracic Cancer
To date, several studies have described the mechanism of resistance to first‐ or second‐generation anaplastic lymphoma kinase (ALK) inhibitors. Secondary ALK mutations, ALK gene amplification, and other bypass signal activations (i.e., KRAS mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7656b36bd83f75d52a1ec1189a10840c
https://doaj.org/article/6062030a7e4a4985952926928c893f1d
https://doaj.org/article/6062030a7e4a4985952926928c893f1d
Autor:
Shu Ching Yang, Nan Haw Chow, Hung Wen Tsai, Yi Lin Chen, Wan Li Chen, Yi Chia Cheng, Ming Ching Lin, Chung Liang Ho, Wu Chou Su, Chien Chung Lin
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0257152 (2021)
PLoS ONE
PLoS ONE
Approximately 5–7% of non–small cell lung cancer (NSCLC) cases harbor an anaplastic lymphoma kinase (ALK) fusion gene and may benefit from ALK inhibitor therapy. To detect ALK fusion genes, we developed a novel test using reverse transcription po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355452b6148c9af2365141e1010607f4
https://doaj.org/article/f237227974f540cd9dec0686f2f84839
https://doaj.org/article/f237227974f540cd9dec0686f2f84839
Autor:
Gaetano Rocco, Rosario Salvi, Stefano Ferrero, Mariacarolina Micheli, Alessandro Palleschi, Danilo Rocco, Federica Zito Marino, Renato Franco, Pietro Micheli, Rossella De Cecio, Gabriella Gaudioso, Gabriella Aquino, Antonio Giordano, Gerardo Botti, Alessandro Morabito
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 4927, p 4927 (2020)
Volume 21
Issue 14
International Journal of Molecular Sciences, Vol 21, Iss 4927, p 4927 (2020)
Volume 21
Issue 14
Background: The Anaplastic Lymphoma Kinase (ALK) gene is known to be affected by several genetic alterations, such as rearrangement, amplification and point mutation. The main goal of this study was to comprehensively analyze ALK amplification (ALK-A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760ae462735b1e29ecfb817e2dce8221
http://europepmc.org/articles/PMC7404032
http://europepmc.org/articles/PMC7404032
Autor:
Sarita Prabhakaran, Rami Sairafi, T Al-Halouly, Khawla S. Al-Kuraya, Shahab Uddin, Zeenath Jehan, Mohammed Al-Assiri, R Bu, Prashant Bavi, Nasser Al-Sanea, F Al-Dayel
Publikováno v:
British Journal of Cancer
Background: Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and haematological tumours. ALK gene copy number changes and mutations in colorectal cancers (CRCs) are not well characterised. We aimed to study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33fc9521cef9c8044312a0e088cb7336
https://doi.org/10.1038/bjc.2013.641
https://doi.org/10.1038/bjc.2013.641
Autor:
Ewelina Rydzik, Ewa Kalinka-Warzocha, Jerzy Kozielski, Alina Knopik-Dąbrowicz, Kamila Wojas-Krawczyk, Paweł Krawczyk, Łukasz Spychalski, Janusz Milanowski, Aleksandra Szczesna, Justyna Szumiło, Maciej Bryl, Rodryg Ramlau
Publikováno v:
Contemporary Oncology
Introduction: ALK gene rearrangement is observed in a small subset (3–7%) of non-small cell lung cancer (NSCLC) patients. The efficacy of crizotinib was shown in lung cancer patients harbouring ALK rearrangement. Nowadays, the analysis of ALK gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bddd8d2ad260249e284c86739adf94b
http://europepmc.org/articles/PMC3934043
http://europepmc.org/articles/PMC3934043
Autor:
Ryohei Katayama, Maria E. Arcila, Mark M. Awad, Gregory J. Riely, Mari Mino-Kenudson, A. John Iafrate, Justin F. Gainor, Jeffrey A. Engelman, Marc Ladanyi, Dora Dias-Santagata, Sai-Hong Ignatius Ou, Alice T. Shaw, Beow Y. Yeap, Amanda C. Pawlak, Sheheryar Kabraji, Anna M. Varghese
Publikováno v:
Clinical Cancer Research. 19:4273-4281
Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct molecular subset of non–small cell lung cancer (NSCLC). Recently, several case reports and small series have reported that ALK rearrangements can overlap with other onc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ed92a1f8abd2fa6d390db181993da6
https://doi.org/10.1158/1078-0432.ccr-13-0318
https://doi.org/10.1158/1078-0432.ccr-13-0318
Autor:
Damianos P. Sakas, Dina Tiniakos, Varvara Pantelaion, Theodosis Kalamatianos, Dimitra Rontogianni, George Stranjalis, Spyridon Komaitis, Konstantinos Mastoris, Theodore Argyrakos, George Karagkounis
Publikováno v:
Journal of clinical pathology. 70(7)
AimsTo study anaplastic lymphoma kinase (ALK) protein expression and possible underlying gene alterations in glioblastoma (GBM), correlating them with clinical outcome.MethodsWe studied ALK immunohistochemical expression and fluorescent in situ hybri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c662febe8c8e03521d29108219e2b411
https://pubmed.ncbi.nlm.nih.gov/27993946
https://pubmed.ncbi.nlm.nih.gov/27993946
Autor:
MC Wright, Massimo Cristofanilli, Fredika M. Robertson, J Jin, Sanford H. Barsky, H Liu, Xiaomei Zhang, AE Ochoa, Zaiming Ye, Khoi Chu
Publikováno v:
Cancer Research. 72:P6-10
Background: Genetic abnormalities in the anaplastic lymphoma kinase (ALK) gene result in activation of signaling pathways including Akt, mTor, and JAK/Stat3. ALK has been shown to be a primary oncogenic driver in a variety of human tumors, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4716e5f9d2ce145ee093592678fcef73
https://doi.org/10.1158/0008-5472.sabcs12-p6-10-04
https://doi.org/10.1158/0008-5472.sabcs12-p6-10-04
Autor:
Tetsuya Yamada, Toshiaki Kunimura, Gabriella Sozzi, Patrizia Gasparini, Federica Perrone, Alberto Cavazza, Mauro Papotti, Paolo Graziano, Mattia Barbareschi, Marina Chiara Garassino, Paolo Scanagatta, Filippo de Braud, Yukio Nakatani, Giuseppe Pelosi, Massimo Barberis, Masayuki Takagi, Giulio Rossi, Ugo Pastorino
Publikováno v:
Lung Cancer. 77:507-514
Background Genetic alterations for targeting therapy are largely unexplored issues in pulmonary sarcomatoid carcinoma (PSC), a life-threatening tumor subset. Methods EGFR , HER2 , KRAS , p53 , CTNNB1 , BRAF and PIK3CA mutations were assessed by direc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce2050beaf7aeef2e7300d76cea3969a
https://doi.org/10.1016/j.lungcan.2012.05.093
https://doi.org/10.1016/j.lungcan.2012.05.093
Autor:
Toshiro Niki, Shoji Ohno, Yukihiko Sugiyama, Hiroyuki Aburatani, Hideki Watanabe, Masashi Bando, Shunpei Ishikawa, Hiroyuki Mano, Munehiro Enomoto, Shuji Takada, Shin-ichiro Fujiwara, Yuichi Ishikawa, Young Lim Choi, Yasunori Sohara, Kentaro Kurashina, Yoshihiro Yamashita, Hisashi Hatanaka, Manabu Soda
Publikováno v:
Nature. 448:561-566
Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c40bb2000fd46a8225116fdf79eea7
https://doi.org/10.1038/nature05945
https://doi.org/10.1038/nature05945